Clinical trials: Crohn Disease in Remission
- Condition Crohn Disease in Remission
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Crohn's Disease
A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease
The purpose of this study is to demonstrate the efficacy and safety of adalimumab for the induction of clinical remission in Japanese subjects with Crohn's disease.
- Trial name
- NCT00445939
- Testing
- adalimumab
- Where
- 18 sites in Japan
- Volunteers
- 90 people
- Sponsor
- Abbott
Crohn's Disease
An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease
The purpose of this study is to see if Epanova™ is able to maintain the symptomatic remission in subjects with Crohn's Disease who are responding to steroid induction therapy.
- Trial name
- NCT00074542
- Testing
- Epanova™ (Omega-3 Free Fatty Acids)
- Where
- 31 sites in United States, Canada
- Volunteers
- 364 people
- Sponsor
- Tillotts Pharma AG
Crohn's Disease
Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease
This is a multi-centre, open-label extension study in subjects who showed clinical response to induction therapy in the treatment of subjects with active Crohn's disease in the double-blind main study C87037 (NCT00291668).
- Trial name
- NCT00329550
- Testing
- Certolizumab pegol (CZP)
- Where
- 23 sites in Japan
- Volunteers
- 40 people
- Sponsor
- UCB Japan Co. Ltd.
Crohn's Disease
A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease
To demonstrate the efficacy and safety of adalimumab for the maintenance of clinical remission in Japanese subjects with Crohn's disease.
- Trial name
- NCT00445432
- Testing
- adalimumab
- Where
- 29 sites in Japan
- Volunteers
- 82 people
- Sponsor
- Abbott
Crohn's Disease
Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)
This 26-week extension study evaluates the efficacy and safety of certolizumab pegol administered subcutaneously every 4 weeks (dosed at Weeks 16, 20, 24, 28 and 32) in subjects with active Crohn's disease who had no clinical…
- Trial name
- NCT00329420
- Testing
- Certolizumab pegol
- Where
- 23 sites in Japan
- Volunteers
- 46 people
- Sponsor
- UCB Pharma